Associations Between Cannabis Use and Cardiometabolic Risk Factors

A Longitudinal Study of Men

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: This study tested longitudinal associations between cannabis use and cardiometabolic risk factors that underlie the development of cardiovascular diseases. Methods: Participants were men from the youngest cohort of the Pittsburgh Youth Study who were followed prospectively from approximately age 7 to 32 years (N = 253). Frequency of cannabis use was assessed yearly from approximately ages 12 to 20 years and again at approximately ages 26, 29, and 32 years. The following cardiometabolic risk factors were assessed during a laboratory visit at approximately age 32 years: body mass index (BMI), waist-hip ratio, high- and low-density lipoprotein cholesterol, triglycerides, fasting glucose, insulin resistance, blood pressure, interleukin 6, and C-reactive protein. Results: Greater cannabis exposure was associated with relatively lower BMI (β = -0.31, p <.001), smaller waist-hip ratio (β = -0.23, p =.002), better high- (β = 0.14, p =.036) and low-density lipoprotein cholesterol (β = -0.15, p =.026), lower triglycerides (β = -0.17, p =.009), lower fasting glucose (β = -0.15, p <.001) and insulin resistance (β = -0.21, p =.003), lower systolic (β = -0.22, p <.001) and diastolic blood pressure (β = -0.15, p =.028), and fewer metabolic syndrome criteria (β = -0.27, p <.001). With exception of BMI, cannabis users' mean levels on cardiometabolic risk factors were generally below clinical cutoffs for high risk. Most associations between cannabis use and cardiometabolic risk factors remained after adjusting for tobacco use, childhood socioeconomic status, and childhood health. However, after adjusting for adult BMI, these associations were no longer apparent, and mediation tests suggested that cannabis users' relatively lower BMI might explain their lower levels of risk on other cardiometabolic risk factors. Conclusions: Cannabis use is associated with lower BMI, and lower BMI is related to lower levels of risk on other cardiometabolic risk factors.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalPsychosomatic Medicine
Volume81
Issue number3
DOIs
StatePublished - Apr 1 2019

Fingerprint

Cannabis
Longitudinal Studies
Body Mass Index
Waist-Hip Ratio
Blood Pressure
LDL Cholesterol
Insulin Resistance
Fasting
Glucose
Tobacco Use
Social Class
C-Reactive Protein
Interleukin-6
Triglycerides
Cardiovascular Diseases
Health

Keywords

  • cannabis
  • cardiometabolic
  • cardiovascular
  • health
  • marijuana

ASJC Scopus subject areas

  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Associations Between Cannabis Use and Cardiometabolic Risk Factors : A Longitudinal Study of Men. / Meier, Madeline; Pardini, Dustin; Beardslee, Jordan; Matthews, Karen A.

In: Psychosomatic Medicine, Vol. 81, No. 3, 01.04.2019, p. 281-288.

Research output: Contribution to journalArticle

@article{741fe97c1b004b13b57ab1ae058b5efe,
title = "Associations Between Cannabis Use and Cardiometabolic Risk Factors: A Longitudinal Study of Men",
abstract = "Objective: This study tested longitudinal associations between cannabis use and cardiometabolic risk factors that underlie the development of cardiovascular diseases. Methods: Participants were men from the youngest cohort of the Pittsburgh Youth Study who were followed prospectively from approximately age 7 to 32 years (N = 253). Frequency of cannabis use was assessed yearly from approximately ages 12 to 20 years and again at approximately ages 26, 29, and 32 years. The following cardiometabolic risk factors were assessed during a laboratory visit at approximately age 32 years: body mass index (BMI), waist-hip ratio, high- and low-density lipoprotein cholesterol, triglycerides, fasting glucose, insulin resistance, blood pressure, interleukin 6, and C-reactive protein. Results: Greater cannabis exposure was associated with relatively lower BMI (β = -0.31, p <.001), smaller waist-hip ratio (β = -0.23, p =.002), better high- (β = 0.14, p =.036) and low-density lipoprotein cholesterol (β = -0.15, p =.026), lower triglycerides (β = -0.17, p =.009), lower fasting glucose (β = -0.15, p <.001) and insulin resistance (β = -0.21, p =.003), lower systolic (β = -0.22, p <.001) and diastolic blood pressure (β = -0.15, p =.028), and fewer metabolic syndrome criteria (β = -0.27, p <.001). With exception of BMI, cannabis users' mean levels on cardiometabolic risk factors were generally below clinical cutoffs for high risk. Most associations between cannabis use and cardiometabolic risk factors remained after adjusting for tobacco use, childhood socioeconomic status, and childhood health. However, after adjusting for adult BMI, these associations were no longer apparent, and mediation tests suggested that cannabis users' relatively lower BMI might explain their lower levels of risk on other cardiometabolic risk factors. Conclusions: Cannabis use is associated with lower BMI, and lower BMI is related to lower levels of risk on other cardiometabolic risk factors.",
keywords = "cannabis, cardiometabolic, cardiovascular, health, marijuana",
author = "Madeline Meier and Dustin Pardini and Jordan Beardslee and Matthews, {Karen A.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/PSY.0000000000000665",
language = "English (US)",
volume = "81",
pages = "281--288",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Associations Between Cannabis Use and Cardiometabolic Risk Factors

T2 - A Longitudinal Study of Men

AU - Meier, Madeline

AU - Pardini, Dustin

AU - Beardslee, Jordan

AU - Matthews, Karen A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objective: This study tested longitudinal associations between cannabis use and cardiometabolic risk factors that underlie the development of cardiovascular diseases. Methods: Participants were men from the youngest cohort of the Pittsburgh Youth Study who were followed prospectively from approximately age 7 to 32 years (N = 253). Frequency of cannabis use was assessed yearly from approximately ages 12 to 20 years and again at approximately ages 26, 29, and 32 years. The following cardiometabolic risk factors were assessed during a laboratory visit at approximately age 32 years: body mass index (BMI), waist-hip ratio, high- and low-density lipoprotein cholesterol, triglycerides, fasting glucose, insulin resistance, blood pressure, interleukin 6, and C-reactive protein. Results: Greater cannabis exposure was associated with relatively lower BMI (β = -0.31, p <.001), smaller waist-hip ratio (β = -0.23, p =.002), better high- (β = 0.14, p =.036) and low-density lipoprotein cholesterol (β = -0.15, p =.026), lower triglycerides (β = -0.17, p =.009), lower fasting glucose (β = -0.15, p <.001) and insulin resistance (β = -0.21, p =.003), lower systolic (β = -0.22, p <.001) and diastolic blood pressure (β = -0.15, p =.028), and fewer metabolic syndrome criteria (β = -0.27, p <.001). With exception of BMI, cannabis users' mean levels on cardiometabolic risk factors were generally below clinical cutoffs for high risk. Most associations between cannabis use and cardiometabolic risk factors remained after adjusting for tobacco use, childhood socioeconomic status, and childhood health. However, after adjusting for adult BMI, these associations were no longer apparent, and mediation tests suggested that cannabis users' relatively lower BMI might explain their lower levels of risk on other cardiometabolic risk factors. Conclusions: Cannabis use is associated with lower BMI, and lower BMI is related to lower levels of risk on other cardiometabolic risk factors.

AB - Objective: This study tested longitudinal associations between cannabis use and cardiometabolic risk factors that underlie the development of cardiovascular diseases. Methods: Participants were men from the youngest cohort of the Pittsburgh Youth Study who were followed prospectively from approximately age 7 to 32 years (N = 253). Frequency of cannabis use was assessed yearly from approximately ages 12 to 20 years and again at approximately ages 26, 29, and 32 years. The following cardiometabolic risk factors were assessed during a laboratory visit at approximately age 32 years: body mass index (BMI), waist-hip ratio, high- and low-density lipoprotein cholesterol, triglycerides, fasting glucose, insulin resistance, blood pressure, interleukin 6, and C-reactive protein. Results: Greater cannabis exposure was associated with relatively lower BMI (β = -0.31, p <.001), smaller waist-hip ratio (β = -0.23, p =.002), better high- (β = 0.14, p =.036) and low-density lipoprotein cholesterol (β = -0.15, p =.026), lower triglycerides (β = -0.17, p =.009), lower fasting glucose (β = -0.15, p <.001) and insulin resistance (β = -0.21, p =.003), lower systolic (β = -0.22, p <.001) and diastolic blood pressure (β = -0.15, p =.028), and fewer metabolic syndrome criteria (β = -0.27, p <.001). With exception of BMI, cannabis users' mean levels on cardiometabolic risk factors were generally below clinical cutoffs for high risk. Most associations between cannabis use and cardiometabolic risk factors remained after adjusting for tobacco use, childhood socioeconomic status, and childhood health. However, after adjusting for adult BMI, these associations were no longer apparent, and mediation tests suggested that cannabis users' relatively lower BMI might explain their lower levels of risk on other cardiometabolic risk factors. Conclusions: Cannabis use is associated with lower BMI, and lower BMI is related to lower levels of risk on other cardiometabolic risk factors.

KW - cannabis

KW - cardiometabolic

KW - cardiovascular

KW - health

KW - marijuana

UR - http://www.scopus.com/inward/record.url?scp=85062295406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062295406&partnerID=8YFLogxK

U2 - 10.1097/PSY.0000000000000665

DO - 10.1097/PSY.0000000000000665

M3 - Article

VL - 81

SP - 281

EP - 288

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 3

ER -